Cell therapy with autologous bone marrow mononuclear stem cells is associated with superior cardiac recovery compared with use of nonmodified mesenchymal stem cells in a canine model of chronic myocardial infarction

Maisonneuve, Mathieu; Bartúnek, Jozef; Oumeiri, Bachar El; Touihri, Karim; Hadad, Ielham; Thoma, Philippe; Metens, Thierry; Costa, Agnès Mendes Da; Mahmoudabady, Maryam; Egrise, Dominique; Blocklet, Didier; Mazouz, Naima; Naeije, Robert; Heyndrickx, Guy R.; McEntee, Kathleen

doi:10.1016/j.jtcvs.2008.12.031

Cited by 57 publications

(43 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The use of autologous bone marrow mononuclear stem cells in a canine model of chronic myocardial infarction has been associated with superior cardiac recovery [11]. We choose to applicate autologous CD34-enriched PBMSC intramyocardially in open heart surgery because stem cells are found in low quantities in old infarcted tissue, and because intracoronary perfusion doesn't guarantee the arrival of adequate number of cells nto the damaged zone, and can induce restenosis [12].…”

Section: Discussionmentioning

confidence: 99%

Efficacy and long-term evaluation of intramyocardial injection of autologous CD34-enriched PBMSC in old myocardial infarction

Aceves¹,

Archundia²,

Páez³

et al. 2012

WJCD

View full text Add to dashboard Cite

Aims: We have shown that autologous transplant of CD34 + -enriched peripheral-blood mononuclear cells (PBMSC) could restore depressed myocardial function, and sustain adequate myocardial function 12 months after surgery in patients with old (>one yearold) myocardial infarction. Our aim is to report the long-term morbidity and mortality efficacy of this procedure. Methods and results: Seventy patients with an old anteroseptal myocardial infarction were followed for 2 to 7 years, 35 had a revascularization procedure and received an intra-myocardial injection of autologous CD34 + -enriched PBMSC (8 × 10 8 mononuclear cells/ml including 3 × 10 7 CD34 + cells/ml)(Group A). Group B patients only had the revascularization. Abnormal pre-surgical values of LVEF (33.2% ± 4.8%), LVDV (178 ± 13.7 ml), LVSV (120 ± 16 m), LVDD (58.9 ± 3.84 mm), E and A waves without contractility in infarction area in group A patients improved to approximate normal values (50% ± 3% for LVEF; 90 ± 9.3 ml for LVDV; 80 ± 9.9 ml for LVSV; 55.3 ± 3 mm for LVDD; 5.2 ± 0.5 cm/s for E wave and 4.18 ± 0.3 cm/s for A wave) 1 year after the procedure and have remained unaltered for all the follow-up period. All the patients remain alive. Only seven patients have been readmitted to the hospital for non-myocardial related events. Group B only 11 patients continued alive to 5 years after surgery and LEVF never increased more than 6%, all of them with many hospitalizations (n ≥ 10) by heart failure events. Conclusion: Intramyocardial injection of CD34 + highly enriched PBSC represent an encouraging alternative for patients with severely scarred and dysfunctional myocardium.

show abstract

Section: Discussionmentioning

confidence: 99%

Efficacy and long-term evaluation of intramyocardial injection of autologous CD34-enriched PBMSC in old myocardial infarction

Aceves¹,

Archundia²,

Páez³

et al. 2012

WJCD

View full text Add to dashboard Cite

show abstract

“…28 Although direct suture to achieve closure is the simplest way of managing a pressure ulcer, this frequently leads to wound dehiscence 29 32 Using the entire mononuclear fraction, no potentially beneficial cell type is omitted and the functional response will depend on the equilibrium between cell types. 33 In contrast, before their uses for cell therapy, autologous MSCs need to be cultured and this determines contamination risks and treatment delay, which increase treatment costs. Moreover, the culture process may interfere with optimal transplantation protocols that requires acute or subacute delivery for best possible results.…”

Section: Discussionmentioning

confidence: 99%

Treatment of pressure ulcers with autologous bone marrow nuclear cells in patients with spinal cord injury

Sarasua

López

Viejo

et al. 2011

The Journal of Spinal Cord Medicine

View full text Add to dashboard Cite

Context: Pressure ulcers are especially difficult to treat in patients with spinal cord injury (SCI) and recurrence rates are high. Prompted by encouraging results obtained using bone marrow stem cells to treat several diseases including chronic wounds, this study examines the use of autologous stem cells from bone marrow to promote the healing of pressure ulcers in patients with SCI. Objective: To obtain preliminary data on the use of bone marrow mononuclear cells (BM-MNCs) to treat pressure ulcers in terms of clinical outcome, procedure safety, and treatment time. Participants: Twenty-two patients with SCI (19 men, 3 women; mean age 56.41 years) with single type IV pressure ulcers of more than 4 months duration. Interventions: By minimally invasive surgery, the ulcers were debrided and treated with BM-MNCs obtained by Ficoll density gradient separation of autologous bone marrow aspirates drawn from the iliac crest. Results: In 19 patients (86.36%), the pressure ulcers treated with BM-MNCs had fully healed after a mean time of 21 days. The number of MNCs isolated was patient dependent, although similar clinical outcomes were observed in each case. Compared to conventional surgical treatment, mean intra-hospital stay was reduced from 85.16 to 43.06 days. Following treatment, 5 minutes of daily wound care was required per patient compared to 20 minutes for conventional surgery. During a mean follow-up of 19 months, none of the resolved ulcers recurred. Conclusions: Our data indicate that cell therapy using autologous BM-MNCs could be an option to treat type IV pressure ulcers in patients with SCI, avoiding major surgical intervention.

show abstract

“…Mathieu et al [113] compared autologous bone marrow derived cells and mesenchymal stem cells in a canine model of chronic myocardial infarction. After cell transfer contractility, regional systolic function and reduction in infarct size were improved in the mononuclear group mainly due to neovascularization.…”

Section: Bone Marrow-derived Stem Cellsmentioning

confidence: 99%

Stem cells as therapy for cardiac disease — a review

Jezierska-Woźniak

Mystkowska²,

Tutas³

et al. 2011

Folia Histochem Cytobiol.

View full text Add to dashboard Cite

Acute myocardial infarction (AMI) is one of the most significant causes of morbidity and mortality worldwide. Stem cells represent an enormous chance to rebuild damaged heart tissue. Correct definition of the cardiac progenitors is necessary to understand heart development, and would pave the way for the use of cardiac progenitors in the treatment of heart disease. Identifying, purifying and differentiating native cardiac progenitor cells are indispensable if we are to overcome congenital and adult cardiac diseases. To understand their functions, physiology and action, cells are tested in animal models, and then in clinical trials. But because clinical trials yield variable results, questions about proper cardiac stem cells remain unanswered. Transplanted stem cells release soluble factors, acting in a paracrine fashion, which contributes to cardiac regeneration. Cytokines and growth factors have cytoprotective and neovascularizing functions, and may activate resident cardiac stem cells. Understanding all these mechanisms is crucial to overcoming heart diseases. (Folia Histochemica et

show abstract

Cell therapy with autologous bone marrow mononuclear stem cells is associated with superior cardiac recovery compared with use of nonmodified mesenchymal stem cells in a canine model of chronic myocardial infarction

Cited by 57 publications

References 29 publications

Efficacy and long-term evaluation of intramyocardial injection of autologous CD34-enriched PBMSC in old myocardial infarction

Efficacy and long-term evaluation of intramyocardial injection of autologous CD34-enriched PBMSC in old myocardial infarction

Treatment of pressure ulcers with autologous bone marrow nuclear cells in patients with spinal cord injury

Stem cells as therapy for cardiac disease — a review

Contact Info

Product

Resources

About

Cell therapy with autologous bone marrow mononuclear stem cells is associated with superior cardiac recovery compared with use of nonmodified mesenchymal stem cells in a canine model of chronic myocardial infarction

Cited by 57 publications

References 29 publications

Efficacy and long-term evaluation of intramyocardial injection of autologous CD34-enriched PBMSC in old myocardial infarction

Efficacy and long-term evaluation of intramyocardial injection of autologous CD34-enriched PBMSC in old myocardial infarction

Treatment of pressure ulcers with autologous bone marrow nuclear cells in patients with spinal cord injury

Stem cells as therapy for cardiac disease &#8212; a review

Contact Info

Product

Resources

About

Stem cells as therapy for cardiac disease — a review